Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

Executive Summary/Abstract Background Bullying first emerged as an important topic of
research in the 1980s in Norway (Olweus), and a recent meta‐analysis shows that these …

Combination therapy with three antiretroviral agents has been integral to successful HIV-1
treatment since 1996. Although the efficacy, adverse effects, and toxicities of contemporary …

People living with HIV (PLWHIV) present an increased risk of adverse cardiovascular
events. We aimed to assess whether antiretroviral therapy (ART) pharmacologically …

HIV type 1 (HIV-1) is the causative agent of AIDS. Since the start of the epidemic, HIV/AIDS
has been responsible for≈ 40 million deaths. Additionally, an estimated 39 million people …

Highly active antiretroviral treatment has led to unprecedented efficacy and tolerability in
people living with HIV. This effect was also observed in the central nervous system with the …

Although the underlying mechanisms driving human immunodeficiency virus (HIV)-mediated
cardiovascular diseases (CVD) onset and progression remain unclear, the role of chronic …

Combination antiretroviral therapy (ART) is effective at suppressing HIV viremia to achieve
persistently undetectable levels in peripheral blood in the majority of individuals with access …

Background Meeting the challenge of antiretroviral therapy (ART) whose efficacy can last a
lifetime requires continuous updating of the virological, pharmacological, and quality of life …

During the last 30 years, antiretroviral treatment (ART) for human immunodeficiency virus
(HIV) infection has been continuously evolving. Since 1996, three-drug regimens (3DR) …